ICH M4Q(R2) 质量指南:人用药品注册通用技术文档 (CTD):质量
VIP免费
i
INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL
REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE
ICH HARMONISED GUIDELINE
THE COMMON TECHNICAL DOCUMENT FOR
THE REGISTRATION OF PHARMACEUTICALS
FOR HUMAN USE: QUALITY
M4Q(R2)
Draft version
Endorsed on 14 May 2025
Currently under public consultation
At Step 2 of the ICH Process, a consensus draft text or guideline, agreed by the
appropriate ICH Expert Working Group, is transmitted by the ICH Assembly to the
regulatory authorities of the ICH regions for internal and external consultation,
according to national or regional procedures.
M4Q(R2)
Document History
Code
History
Date
M4Q(R2)
Endorsement by the Members of the ICH
Assembly under Step 2 and release for public
consultation.
14 May 2025
Legal notice: This document is protected by copyright and may, with the exception of the ICH
logo, be used, reproduced, incorporated into other works, adapted, modified, translated or
distributed under a public license provided that ICH's copyright in the document is
acknowledged at all times. In case of any adaption, modification or translation of the document,
reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes
were made to or based on the original document. Any impression that the adaption,
modification or translation of the original document is endorsed or sponsored by the ICH must
be avoided.
The document is provided "as is" without warranty of any kind. In no event shall the ICH or the
authors of the original document be liable for any claim, damages or other liability arising from
the use of the document.
The above-mentioned permissions do not apply to content supplied by third parties. Therefore,
for documents where the copyright vests in a third party, permission for reproduction must be
obtained from this copyright holder.
iii
ICH HARMONISED GUIDELINE
THE COMMON TECHNICAL DOCUMENT FOR THE
REGISTRATION OF PHARMACEUTICALS FOR
HUMAN USE: QUALITY
M4Q(R2)
ICH Consensus Guideline
TABLE OF CONTENTS
SCOPE AND ORGANISATION ...................................................................................................... 1
MODULE 2. COMMON TECHNICAL DOCUMENT SUMMARIES ....................................... 4
2.3. Quality Overview ..........................................................................................................................4
2.3.1 General Information....................................................................................................................4
2.3.2 Overall Development and Overall Control Strategy.................................................................. 4
2.3.2.1 Quality Target Product Profile ...................................................................................... 4
2.3.2.2 Overall Development Strategy ...................................................................................... 5
2.3.2.3 Overall Control Strategy Representation ...................................................................... 5
2.3.3 Core Quality Information........................................................................................................... 5
2.3.3.DS Drug Substances.........................................................................................................5
2.3.3.SI Substance Intermediates, if Applicable ........................................................................ 8
2.3.3.SM Starting/Source Materials .......................................................................................... 9
2.3.3.RM Raw Materials ............................................................................................................9
2.3.3.EX Excipients................................................................................................................. 10
2.3.3.RS Reference Standards and/or Materials ......................................................................11
2.3.3.DP Drug Products .......................................................................................................... 12
2.3.3.PI Product Intermediates, if Applicable ......................................................................... 14
2.3.3.MD Medical Devices, if Applicable ................................................................................14
2.3.3.PM Packaged Medicinal Products for multiconstituent products, if Applicable........... 16
2.3.3.PH Pharmaceutical Product after transformation, if Applicable.................................. 17
2.3.3.AP Analytical Procedures ...............................................................................................17
2.3.3.FA Facilities....................................................................................................................18
2.3.4 Development Summary and Justification .................................................................................18
2.3.4.IN Integrated Development and Justifications ...............................................................18
2.3.4.DS Drug Substances.......................................................................................................20
摘要:
展开>>
收起<<
iINTERNATIONALCOUNCILFORHARMONISATIONOFTECHNICALREQUIREMENTSFORPHARMACEUTICALSFORHUMANUSEICHHARMONISEDGUIDELINETHECOMMONTECHNICALDOCUMENTFORTHEREGISTRATIONOFPHARMACEUTICALSFORHUMANUSE:QUALITYM4Q(R2)DraftversionEndorsedon14May2025CurrentlyunderpublicconsultationAtStep2oftheICHProcess,aconsensusdraftt...
声明:如果您的权利被侵害,请联系我们的进行举报。
相关推荐
-
ASTM F3172-15 血管内医疗器械设计验证数量和样本容量选择指南
2024-04-15 136 -
ASTM-D-882-测量塑料薄膜和薄片材拉伸性能(
2024-04-16 97 -
ASTM F838-2015 确定用于液体过滤的膜过滤器的细菌滞留的标准试验方法
2024-05-09 96 -
ASTM F3064-21 Standard Specification for Normal Category Aeroplanes CertificationVIP免费
2024-05-09 54 -
ASTM D3195 D3195M-10(2015) Standard Practice for Rotameter CalibrationVIP免费
2024-05-09 63 -
ASTM D4169-22 运输集装箱和系统的性能测试1(中文版)VIP免费
2025-09-09 48 -
ASTM D4169 运输集装箱和设备性能试验的标准实施规范(中英文)VIP免费
2025-09-09 36 -
ASTME2500 确证方法--关键质量属性关键工艺参数关键方面VIP免费
2025-09-26 21 -
ASTM E2500-25 药品的规格、设计与验证以及生物制药生产系统装备科学与基于风险的方法1(中文)VIP免费
2025-11-21 80 -
ASTM E3219-25 基于健康的暴露限值(HBEL)推导指南(中文)
2025-12-17 56
作者:冒牌货
分类:法规规范
价格:80质量币
属性:59 页
大小:569.26KB
格式:PDF
时间:2025-12-22

